We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Begins Safety Review of Remdesivir Patients with Kidney Injuries
EMA Begins Safety Review of Remdesivir Patients with Kidney Injuries
The European Medicines Agency’s (EMA) safety committee has begun a review of acute kidney injuries reported in some COVID-19 patients being treated with Gilead Sciences’ remdesivir.